Crossmark

Impact of cause of death adjudication on the results of the European prostate cancer screening trial

Crossref DOI link: https://doi.org/10.1038/bjc.2016.378

Published Online: 2016-11-17

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Walter, Stephen D

de Koning, Harry J

Hugosson, Jonas

Talala, Kirsi

Roobol, Monique J

Carlsson, Sigrid

Zappa, Marco

Nelen, Vera

Kwiatkowski, Maciej

Páez, Álvaro

Moss, Sue

Auvinen, Anssi
License Information

Text and Data Mining valid from 2016-11-17
More Information

Article History

Received: 16 May 2016

Revised: 22 September 2016

Accepted: 9 October 2016

First Online: 17 November 2016

Competing interests

: Dr Sigrid Carlsson’s work on this paper was supported in part by a Cancer Center Support Grant from the National Cancer Institute made to Memorial Sloane Kettering Cancer Center (P30 CA008748). Dr Carlsson is also supported by a post-doctoral grant from AFA Insurance. Dr Carlsson has received travel reimbursement from Sanofi-aventis. No other authors have any conflicts of interest.